Treatment of Aggressive Non-Hodgkin’s Lymphoma with Chemotherapy in Combination with Filgrastim

@article{Schriber2002TreatmentOA,
  title={Treatment of Aggressive Non-Hodgkin’s Lymphoma with Chemotherapy in Combination with Filgrastim},
  author={Jeff Schriber},
  journal={Drugs},
  year={2002},
  volume={62},
  pages={33-46}
}
Non-Hodgkin’s lymphoma (NHL) is one of the ten most common cancers in the developed world. The incidence has increased significantly over the past two decades and it is a particular burden in patients over the age of 60 years. The gold standard for primary treatment of aggressive NHL is combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Haematological growth factors, such as granulocyte colony-stimulating factor (G-CSF), can be used to ameliorate… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 65 REFERENCES

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review.

  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2001
VIEW 16 EXCERPTS
HIGHLY INFLUENTIAL

Comparison of CHOP chemotherapy with autologous bone marrow trans Filgrastim in the Management of NHL 45 © Adis International Limited

LF Verdonck, WL van Putten, A Hagenbeek
  • All rights reserved
  • 2002
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

N Schmitz, DC Linch, P Dreger
  • Lancet
  • 1996
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Prognostic factors in non-Hodgkin's lymphoma.

  • Current opinion in oncology
  • 1992
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL